Theragnostics has signed a global licensing agreement with Advanced Accelerator Applications (AAA) to develop and commercialize gallium-68 (Ga-68) one-step PET radiopharmaceuticals.
Theragnostics will receive an upfront payment and will be eligible for future royalties on sales of resulting products under the agreement terms. AAA, a Novartis company, has exclusive rights to commercialize PET radiopharmaceuticals developed under the licensed patent.
The goal is for the technology platform being developed to enable the production of Ga-68 radiopharmaceuticals in a single multidose vial in one step, which has the potential to diagnose a broad range of cancers, company leaders said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
